Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholant...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Oncoimmunology Ročník 6; číslo 2; s. e1267892
Hlavní autori: Putz, Eva M., Guillerey, Camille, Kos, Kevin, Stannard, Kimberley, Miles, Kim, Delconte, Rebecca B., Takeda, Kazuyoshi, Nicholson, Sandra E., Huntington, Nicholas D., Smyth, Mark J.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Taylor & Francis 01.02.2017
Taylor & Francis Group
Predmet:
Cancer
cytokine signaling
immunotherapy
metastasis
NK cells
Original Research
cytokine signaling
NK cells
metastasis
immunotherapy
Cancer
ISSN:2162-402X, 2162-4011, 2162-402X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in Cish-deficient mice. The combination of Cish deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Supplemental data for this article can be accessed on the publisher's website.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2016.1267892